Mather Group’s Royalty Pharma RPRX Stock Holding History

Mather Group’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.47K	Hold	25	–	–	﹤0.01%	2104
2026 Q2	$1.42K	Sell	25 -22	-47%	-$1.14K	﹤0.01%	1771
2026 Q1	$2.27K	Buy	+47	New	+$2.06K	﹤0.01%	1687
2025 Q4	–	Sell	-8	Closed	-$290	–	1444
2025 Q3	$290	Buy	+8	New	+$290	﹤0.01%	1657
2025 Q2	–	Sell	-80	Closed	-$2.49K	–	1490
2025 Q1	$2.49K	Buy	+80	New	+$2.54K	﹤0.01%	1540
2024 Q4	–	Sell	-107	Closed	-$3.04K	–	1772
2024 Q3	$3.04K	Buy	107 +91	+569%	+$2.52K	﹤0.01%	1400
2024 Q2	$494	Sell	16 -10	-38%	-$277	﹤0.01%	2073
2024 Q1	$737	Buy	+26	New	+$766	﹤0.01%	1658

Other funds holding RPRX

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Hosking Partners London, United Kingdom $2.81B AUM 67.07% 1-Year Est. Return

Kepler Cheuvreux Nyon $1.65B AUM 36.86% 1-Year Est. Return

Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return

Kirr Marbach & Co Columbus, Indiana $530M AUM 14.37% 1-Year Est. Return

Triasima Portfolio Management Montreal, Quebec, Canada $758M AUM 48.16% 1-Year Est. Return

Fideuram - Intesa Sanpaolo Private Banking Turin $3.5B AUM 45.13% 1-Year Est. Return

Mather Group's RPRX Position: Q3 2026 in Review

Mather Group held its Royalty Pharma (RPRX) position steady in Q3 2026 at 25 shares worth $1.47K. The position accounts for ﹤0.01% of the portfolio, ranked #2104.

Mather Group first reported a position in RPRX in Q1 2024 and has held it in 8 quarters since. The position peaked at $3.04K in Q3 2024. 117 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

Mather Group held 25 shares of Royalty Pharma worth $1.47K as of Q3 2026.
Mather Group left its Royalty Pharma share count unchanged in Q3 2026.
Royalty Pharma made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #2104 holding.
Mather Group first reported a position in Royalty Pharma in Q1 2024 and has held it in 8 quarters since.
Mather Group's Royalty Pharma position peaked at $3.04K in Q3 2024.
117 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.